Access to over-the-counter HRT products comes into force

Used to alleviate menopausal symptoms

Hemma Visavadia
clock • 2 min read

The purchasing of Hormone Replacement Therapy (HRT) products over the counter without needing a prescription has come into force, after being approved by the Medicines and Healthcare products Regulatory Agency (MHRA).

Products such as Gina 10 microgram, which contains estradiol, are used to treat vaginal symptoms such as dryness, soreness, itching and burning in postmenopausal women aged 50 years and above. The product will now be available locally at pharmacies across the UK. The product reclassification follows a safety review by the MHRA, the Commission on Human Medicines (CHM), and a public consultation which received 1229 responses, with over 88% being in favour of the move. The review found that the product was safe enough when supplied from a pharmacy to individuals following a consultation ...

To continue reading this article...

Join COVER for free

  • Unlimited access to real-time news, key trend analysis and industry insights.
  • Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
  • Receive breaking news stories straight to your inbox in the daily newsletter.
  • Members only access to monthly programme 'The COVER Review'
  • Be the first to hear about our CPD accredited events and awards programmes.

Join now

 

Already a Cover member?

Login

More on PMI

Three quarters of adults say private healthcare is unaffordable
PMI

Three quarters of adults say private healthcare is unaffordable

Benenden Health research shows

Jaskeet Briah
clock 26 March 2024 • 2 min read
NFP acquires PMI intermediary
PMI

NFP acquires PMI intermediary

Bolstering employee benefits capabilities

Jaskeet Briah
clock 26 March 2024 • 1 min read
Corporate demand drives insured private health admissions
PMI

Corporate demand drives insured private health admissions

Self-pay admissions are plateauing

Jaskeet Briah
clock 25 March 2024 • 2 min read